Bevacizumab is superior to Temozolomide in causing mitochondrial dysfunction in human brain tumors

• المؤلفون الرئيسيون: Nanegrungsunk D., Apaijai N., Yarana C., Sripetchwandee J., Limpastan K., Watcharasaksilp W., Vaniyapong T., Chattipakorn N., Chattipakorn S.
• التنسيق: دورية
• منشور في: 2017
• الوصول للمادة أونلاين: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84978422190&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/41962
• المؤسسة: Chiang Mai University

© 2016 Informa UK Limited, trading as Taylor & Francis Group. Objective: Current chemotherapy treatments available for treating high-grade brain tumors, Temozolomide (TMZ) or Bevacizumab (BEV), not only have specific anti-tumor mechanisms, but also have an effect on mitochondria. However, effe...